Sandu Pharmaceuticals (524703) Q4 25/26 earnings summary

Executive summary

• Standalone audited financial results for the quarter and year ended 31st March 2026 were approved and published, with an unmodified audit opinion from the statutory auditors.

• Final dividend of Rs. 1 per equity share (10% of face value) recommended for FY 2025-26, subject to shareholder approval.

• Board approved reappointment of cost and internal auditors for FY 2026-27.

Financial highlights

• Revenue from operations for Q4 FY26 was Rs. 1,685.34 lakhs, up from Rs. 1,406.92 lakhs in Q4 FY25.

• Net profit for Q4 FY26 stood at Rs. 97.51 lakhs, compared to Rs. 32.64 lakhs in Q4 FY25.

• For the full year FY26, revenue was Rs. 6,993.45 lakhs (FY25: Rs. 6,719.24 lakhs), and net profit was Rs. 176.61 lakhs (FY25: Rs. 154.89 lakhs).

• Total comprehensive income for FY26 was Rs. 242.95 lakhs, up from Rs. 219.47 lakhs in FY25.

• Earnings per share (EPS) for FY26 was Rs. 1.83, compared to Rs. 1.60 in FY25.

Outlook and guidance

• Board and management continue to focus on core Ayurvedic medicines segment, with no indication of diversification.